Centro de Investigación de Medicina Aplicada (CIMA)

2024

1. A Focus on the Pathophysiology of Adrenomedullin Expression: Endothelitis and Organ Damage in Severe Viral and Bacterial Infections

   Cells, Vol. 13, Núm. 11

2. A mouse model to assess immunotherapy-related colitis

   Methods in Cell Biology (Academic Press Inc.)

3. A road map for the treatment of pediatric diffuse midline glioma

   Cancer Cell

4. AI is a viable alternative to high throughput screening: a 318-target study

   Scientific Reports, Vol. 14, Núm. 1

5. Agrypnia Excitata and Supranuclear Vertical Gaze Palsy Linked to Anti-Ma Encephalitis

   Movement Disorders Clinical Practice, Vol. 11, Núm. 5, pp. 571-574

6. An atlas of cells in the human tonsil

   Immunity, Vol. 57, Núm. 2, pp. 379-399.e18

7. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)

   Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186

8. Anti-miR-873-5p improves alcohol-related liver disease by enhancing hepatic deacetylation via SIRT1

   JHEP Reports, Vol. 6, Núm. 1

9. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

   Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

10. Biomaterials-Based Antioxidant Strategies for the Treatment of Oxidative Stress Diseases

    Biomimetics, Vol. 9, Núm. 1

11. Brain 18F-FDG PET findings and sequential vestibular testing in SCA27B: a case report

    Journal of Neurology

12. CALR but Not JAK2 Mutations Are Associated with an Overexpression of Retinoid X Receptor Alpha in Essential Thrombocythemia

    Cancers, Vol. 16, Núm. 8

13. CD3 aptamers promote expansion and persistence of tumor-reactive T cells for adoptive T cell therapy in cancer

    Molecular Therapy Nucleic Acids, Vol. 35, Núm. 2

14. CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials

    Nature Communications, Vol. 15, Núm. 1

15. Characterization of immune populations in the tumor microenvironment of diffuse midline glioma orthotopic mouse models by flow cytometry

    STAR Protocols, Vol. 5, Núm. 1

16. Chimeric oncolytic adenovirus evades neutralizing antibodies from human patients and exhibits enhanced anti-glioma efficacy in immunized mice

    Molecular Therapy, Vol. 32, Núm. 3, pp. 722-733

17. Considering nutritional status to improve outcomes of patients treated by atezolizumab–bevacizumab for advanced hepatocellular carcinoma

    Liver International

18. Cytogenetic and Molecular Associations with Outcomes in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents plus Venetoclax

    Clinical Cancer Research, Vol. 30, Núm. 7, pp. 1319-1326

19. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming

    Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151

20. DNA electroporation in a vacuum: A “shocking” innovation for vaccines

    Molecular Therapy Nucleic Acids